4D Molecular Therapeutics, Inc. (FDMT) Dividend History

4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company focused on developing targeted gene therapies for various genetic and acquired diseases. Utilizing its proprietary vector platform, 4DMT aims to deliver precise and durable treatments through innovative vector design and delivery methods. The company emphasizes leveraging advanced genetic engineering technologies to create therapies with enhanced specificity and reduced immunogenicity.

5858 Horton Street #455, Emeryville, CA, 94608
Phone: (510) 505-2680
Website: https://www.4dmoleculartherapeutics.com

Dividend History

4D Molecular Therapeutics, Inc. currently does not pay dividends

Company News

Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide

The global gene therapy in ophthalmology market is experiencing robust growth, driven by the increasing prevalence of genetic eye diseases, technological advancements, and regulatory support. However, the high cost of treatments and manufacturing challenges remain key concerns.

GlobeNewswire Inc.
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

GlobeNewswire Inc.

Featured Companies: ADVM BIIB JNJ MGTX PASG RARE RCKT RGNX SRPT TNYA
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

GlobeNewswire Inc.

Featured Companies: ABEO BCLI CAPR EDIT FOLD OCGN PFE RARE RGNX SGMO
4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, a clinical-stage biotechnology company, announced that it will participate in fireside chats at upcoming investor conferences in March. The company's management team will also be available for one-on-one meetings.

GlobeNewswire Inc.
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT announced positive interim data from the Phase 2b cohort of its PRISM study evaluating 4D-150 in wet AMD. The data showed significant reduction in injection burden and durable aflibercept expression, supporting the potential of 4D-150 as a backbone therapy for vascular retinal diseases.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 14:47:53 UTC